On 23 February 2004, orphan designation (EU/3/04/186) was granted by the European Commission to medac Gesellschaft fuer klinische Spezialpräparate mbH, Germany, for treosulfan for the conditioning treatment prior to haematopoietic progenitor cell transplantation.

Please note that this product (marketed as Trecondi) was withdrawn from the Community Register of designated orphan medicinal products by the European Commission in June 2019 at the time of the granting of a marketing authorisation.

Key facts

Active substance
Disease / condition
Conditioning treatment prior to haematopoietic-progenitor-cell transplantation
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Trecondi at the time of marketing authorisation, and recommended that the orphan designation should not be maintained. 
More information is available in the PDF iconorphan medicine assessment report .

Sponsor's contact details

medac Gesellschaft für klinische Spezialpräparate mbH
Theaterstraße 6
D-22880 Wedel
Tel. + 49 4103 8006 0
Fax + 49 4103 8006 100

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating